These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28375820)

  • 1. The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C.
    Yoo ER; Perumpail RB; Cholankeril G; Jayasekera CR; Ahmed A
    Telemed J E Health; 2017 Oct; 23(10):870-873. PubMed ID: 28375820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas.
    Jayasekera CR; Perumpail RB; Chao DT; Pham EA; Aggarwal A; Wong RJ; Ahmed A
    Dig Dis Sci; 2015 Dec; 60(12):3552-7. PubMed ID: 26467703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection.
    Zignego AL; Monti M; Gragnani L
    Acta Biomed; 2018 Oct; 89(3):321-331. PubMed ID: 30333452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder.
    van Seyen M; Samson AD; Cullen L; Eastick K; Knol H; Colbers A; Burger DM
    Int J Antimicrob Agents; 2020 Jun; 55(6):105934. PubMed ID: 32156618
    [No Abstract]   [Full Text] [Related]  

  • 6. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
    Evon DM; Golin CE; Stewart P; Fried MW; Alston S; Reeve B; Lok AS; Sterling RK; Lim JK; Reau N; Sarkar S; Nelson DR; Reddy KR; Di Bisceglie AM
    Contemp Clin Trials; 2017 Jun; 57():58-68. PubMed ID: 28342989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.
    Mir F; Kahveci AS; Ibdah JA; Tahan V
    Drug Des Devel Ther; 2017; 11():497-502. PubMed ID: 28260862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.
    Med Lett Drugs Ther; 2016 Aug; 58(1501):107-8. PubMed ID: 27508349
    [No Abstract]   [Full Text] [Related]  

  • 9. Sofosbuvir and velpatasvir for the treatment of hepatitis C.
    Jackson WE; Everson GT
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):501-505. PubMed ID: 28468532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
    Brieva T; Rivero A; Rivero-Juarez A
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):483-490. PubMed ID: 28165830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Drug Treats All Genotypes of Chronic HCV.
    Aschenbrenner DS
    Am J Nurs; 2016 Oct; 116(10):27. PubMed ID: 27684768
    [No Abstract]   [Full Text] [Related]  

  • 12. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
    Gane EJ; Shiffman ML; Etzkorn K; Morelli G; Stedman CAM; Davis MN; Hinestrosa F; Dvory-Sobol H; Huang KC; Osinusi A; McNally J; Brainard DM; McHutchison JG; Thompson AJ; Sulkowski MS;
    Hepatology; 2017 Oct; 66(4):1083-1089. PubMed ID: 28498551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
    Everson GT; Towner WJ; Davis MN; Wyles DL; Nahass RG; Thuluvath PJ; Etzkorn K; Hinestrosa F; Tong M; Rabinovitz M; McNally J; Brainard DM; Han L; Doehle B; McHutchison JG; Morgan T; Chung RT; Tran TT
    Ann Intern Med; 2015 Dec; 163(11):818-26. PubMed ID: 26551051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of crushed sofosbuvir-velpatasvir in a patient with dysphagia.
    Mogul A; Teixeira E; McAuliffe L; Promrat K; Zullo AR
    Am J Health Syst Pharm; 2020 Mar; 77(6):417-418. PubMed ID: 31930300
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
    Bourgeois S; Van Vlierberghe H; Moreno C; Orlent H; Nevens F; Arastéh K; Horsmans Y; Schattenberg JM; Buggisch P; Francque S; Vijgen L; Kakuda TN; Hoeben E; Luo D; Vandebosch A; Jacquemyn B; Van Remoortere P; Verloes R
    BMC Gastroenterol; 2017 Feb; 17(1):26. PubMed ID: 28187751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.
    Sokol R
    Am Fam Physician; 2017 May; 95(10):664-666. PubMed ID: 28671408
    [No Abstract]   [Full Text] [Related]  

  • 18. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.
    Kanda T
    Hepatol Int; 2017 Jan; 11(1):38-44. PubMed ID: 27282879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral therapy approved for chronic HCV infection of all genotypes.
    Traynor K
    Am J Health Syst Pharm; 2016 Aug; 73(15):1120. PubMed ID: 27440614
    [No Abstract]   [Full Text] [Related]  

  • 20. Resolution of Atypical Lichen Myxedematosus Following Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir-Velpatasvir Combination Therapy.
    Jones KM; Shelton ME; Soldano AC; Campbell J
    JAMA Dermatol; 2018 Sep; 154(9):1094-1096. PubMed ID: 30140911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.